3月10日，君圣泰医药-B(2511.HK)今日高开高走，一度大涨19.25%至3.16港元，股价创年内新高。该股自上周四(3月5日)以来已连续4个交易日上涨，累涨超66%，大幅跑赢大盘及行业表现(同期恒指累涨2.74%，恒生生物科技指数累涨7.73%)。
消息面上，君圣泰医药今年2月上旬举行投资者会议，系统阐述了其以“一药多效”策略引领心肾代谢系统疾病(CKM)综合治疗新时代的战略布局，并解读了多项关键临床进展。华通证券国际曾指，“一药多效”核心产品HTD1801商业化进程提速在即，CKM基石疗法市场空间广阔，给予公司目标价5.78港元，首予“推荐”评级。
此外，交银国际发研报指，年报季临近，建议持续关注财务表现超预期、盈利路径清晰的公司，其业绩兑现有望催化板块行情。该行认为2026年板块稳中向好态势或将延续，但仍有短期波动的可能，在选股时应重回基本面和估值、关注在震荡中被错杀的低估标的。
港股频道更多独家策划、专家专栏，免费查阅>>
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.